777 NW 9th Ave, Suite 404, Corvallis, OR 97330
777 NW 9th Ave, Suite 404, Corvallis, OR 97330
The most common radioisotope used in nuclear medicine procedures in the U.S. is Tc-99m. Tc-99m is used extensively in nuclear cardiology (50% of procedures), nuclear oncology (25%), and in other imaging of the brain, endocrine system, lungs, gastrointestinal, genitourinary, and bones. There are currently 40 million nuclear medicine procedures performed in the U.S. each year, with 80% using Tc-99m based radiopharmaceuticals. Tc-99m is most conveniently obtained from the beta-decay of Mo-99, which has a half-life of
66 hours. Due to the short half-lives of Tc-99m (6 hours) and Mo-99, the isotopes cannot be stockpiled and must be produced in fresh batches and distributed to medical imaging centers almost daily.
NWMI is dedicated to providing a reliable, securable, and affordable source of Mo-99 both domestically and worldwide by early 2023. We have embraced this challenge and will safely apply our technical and project expertise to ensure project success. Our people drive our solution!
Our highly qualified management team includes experts on complex nuclear EPC projects, nuclear reactor licensing, research reactor operations, and nuclear criticality safety who are focused on designing and building a radioisotope production facility (RPF) to deliver in-specification Mo-99 to our customers.
We are committed to advancing radioisotope technology development to support human health advancements and improve lives through the use of medical isotope imaging.
The most common radioisotope used in nuclear medicine procedures in the U.S. is Tc-99m. Tc-99m has found extensive use in nuclear cardiology (50% of procedures), nuclear oncology (25%), and in other imaging of the brain, endocrine system, lungs, gastrointestinal, genitourinary, and bones. There are currently 40 million nuclear medicine procedures performed annually in the U.S., with 80% using Tc-99m based radiopharmaceuticals. Although the radioisotope can be produced directly on a cyclotron or other type of particle accelerator, Tc-99m is most conveniently obtained from the beta-decay of Mo-99. Due to the short half-lives of Tc-99m (6 hours) and Mo-99 (66 hours), the isotopes cannot be stockpiled and must be produced in fresh batches and distributed to medical imaging centers almost daily.
Mo-99 is a fission fragment that is abundantly produced in the neutron-induced fission of U-235 (6% of all fissions). The Tc-99m generators allow a quick and convenient chemical separation of Tc-99m daughter nuclei from the Mo-99 parent material. The 66-hour half-life enables Mo-99 to be produced at large-capacity locations and then transported to centralized radiopharmacies in the U.S., which distribute the Tc-99m generators to hospitals and other imaging facilities. Mo-99 production is typically measured in “6-day curies” based on the material activity 6 days after being shipped (the actual value is roughly four times the 6-day value). The estimated worldwide demand for Mo-99 is ~9,400 6-day Ci per week (2018).
The last commercial production of Mo-99 in the U.S. ended in 1989 and the process was just restarted in 2018. Domestic supply has and will continue to rely on international producers who employed the high efficiency of irradiating highly enriched uranium (HEU) targets, with much of the HEU exported from the U.S. Currently, six multipurpose research reactors, with five of these sites being over 45–55 years old, irradiate HEU or low--enriched uranium (LEU) targets for Mo-99 production. As part of nuclear nonproliferation efforts, under the American Medical Isotope Production Act of 2012, the U.S. must stop exporting HEU by 2020, which is used for targets for isotope production and for fuel for reactors. The industry has largely converted to the use of LEU.
Establish and deliver a domestic reliable, securable source of at least 3,000 6-day curies of Mo-99 weekly, steady-state and without the use of highly enriched uranium
NWMI will design, license, and construct a radioisotope production facility (RPF) to process low-enriched uranium (LEU) targets to produce at least 3,000 6‑day Ci of Mo-99 through a fission-based process. The RPF will house the entire production process, which includes:
The targets will be chemically processed to produce pharmaceutical grade Mo-99. The finished product will be produced using the current established Good Manufacturing Practices program. The process used will also meet FDA requirements applicable to active pharmaceutical ingredients.
The RPF site will be situated within Discovery Ridge Research Park (Discovery Ridge) in Columbia, Missouri. The site is in central Missouri, approximately 125 miles east of Kansas City and 125 miles west of St. Louis. The Missouri River lies 9.5 miles west of the site. The RPF site is located 3.5 mi southeast of the main University of Missouri (MU) campus and occupies 15 acres (Lots 14 and 15) at Discovery Ridge on property owned by MU.
The layout of the NWMI site, including the RPF, is shown at right. Three adjacent, separate buildings will be located on the site, including the Administrative Building (outside of the protected area), Waste Staging and Shipping Building for additional Class A waste storage (inside the protected area), and Diesel Generator Building. These major facilities also receive, store/hold, or process chemicals, oil, diesel fuel, and other hazardous and radioactive materials.
NWMI is producing Mo-99 by reactor fission (splitting a uranium atom).” Uranium fission is considered to be the “gold standard” process for producing Mo-99, as the production process is highly efficient and the Mo-99 produced has a high specific activity (>1,000 Ci/g, making it suitable for use in conventional Tc-99m generators used worldwide.
Typically, targets containing U-235 are placed in a nuclear reactor for about 5 to 7 days to allow Mo-99 to build up to between about 70% and 80% of saturation concentration. The neutrons given off by the nuclear reactor split the U-235 atoms in the targets, continuously creating Mo-99 at a known rate. Whenever the U-235 is split, 6% of the time, one of the fragments created is Mo‑99. Approximately 3% of the U-235 in the target is consumed during irradiation. The targets are removed from the reactor after irradiation and a 24‑hour (approximately) cool-down period is completed.
NWMI has completed the following activities to date:
Radioisotope Production Facility
Research and development (R&D)
University research reactors
Ms. Haass has 36 years of experience on complex nuclear, chemical, hazardous, and mixed-waste EPC projects for government and private industry. She has extensive communications experience in the nuclear and environmental industry, including day-to-day interface with regulators, safety boards, Congress, stakeholders, tribal nations, public, media, community leaders, and decision makers. Ms. Haass has over 10 years of medical isotope production experience and is responsible for development, coordination, and submission to the NRC of the 10CFR50/70 Operating License Application and safety analysis report in support of RPF operations. Under her direction, the RPF Construction Permit Application was submitted to and approved by the NRC in 2018 for the construction of the RPF under 10CFR50.
Mr. Butler has over 36 years of nuclear experience in the management, oversight, and operation of Navy, commercial, university, and DOE facilities, both domestic and international. His experience includes power plant and research reactor operations, program management, quality improvement and assessment activities, and independent safety reviews. He is a Registered Professional Engineer in the state of Missouri and held an NRC Senior Reactor Operator License for Westinghouse Pressurized Water Reactor, Callaway Nuclear Energy Center. He serves as Senior Technical Advisor on the NWMI RFP project and as NWMI's liaison with MURR.
Mr. Corum is a subject matter expert with over 28 years of nuclear industry experience, including 9 years of medical isotope production experience. His broad experience base in nuclear criticality safety includes expertise in radiation shielding, hazards analysis, packaging and transportation, and core reload analysis. He has extensive experience in both facility support and packaging and transportation (fresh and spent fuel). Additional areas of expertise include integrated safety analysis, fault tree analysis, qualitative and quantitative methods of hazards assessment, shielding analysis using MCNP code, validation and benchmarking of criticality codes, nuclear reactor core design, and reactor physics calculations in support of reload safety analysis efforts.
Dr. Reese, Director for the OSU Radiation Center, has 22 years of experience in research reactor operations and has a Senior Reactor Operating license for OSTR. The Center is a multifaceted research facility specializing in research related to the nuclear sciences and houses unique capabilities, including the 1.1 MW OSTR, gamma irradiator, thermal hydraulics testing laboratories, and radiochemistry laboratories. Dr. Reese has been a key contributor to the R&D associated with development and testing of the NWMI RPF targets and in supporting the RPF license application process.
Mr. Dunford’s has over 40 years of experience in plant operations and providing process engineering support to radioactive/mixed waste facilities and on medical isotope production facilities. His experience extends to systems engineering applications, flowsheet development, conduct of operations principles, operational readiness activities, safety documentation preparation, and authorization basis implementation. For the past 10 years, Mr. Dunford has supported NWMI facility design of the RPF process systems and development of the RPF license applications and safety analysis.
Mr. Molen leads McCarthy’s Advanced Technology & Manufacturing business unit. He has successfully delivered complex laboratory and manufacturing construction projects and nuclear-grade facilities to public entities such as DOE, Oak Ridge National Laboratory, General Services Administration, Department of Veteran’s Affairs, and numerous private clients. He will direct pre-construction and construction activities for the NWMI RPF and associated support facilities.
Ms. Petermann is a Technical Communications specialist, with over 38 years of experience working on technical and cost proposals for various industries and clients, and special projects in the areas of nuclear waste management/cleanup, transportation systems, and computer systems development. Her areas of expertise include proposal development, technical writing and editing, graphics design and editing, promotional materials design and production, and computer systems development and implementation. She has supported NWMI communication activities since 2013 and played a key role in the development of the RPF Construction Permit Application and associated documentation submitted to and approved by the NRC in 2018.
NWMI is an emerging leader with new solutions in nuclear medicine technology:
NWMI currently has no open positions or job postings. Check back on this webpage for future job postings in the Columbia, Missouri area.
NWMI will participate in local career fairs when hiring begins to ramp-up. Dates, times, and locations will be posted on this webpage.
NWMI will offer a competitive benefits package to full-time NWMI employees. Details will be provided during the interview process.
777 NW 9th Ave, Suite 404, Corvallis, OR 97330